Patiromer

Patiromer has demonstrated efficacy and safety in outpatient populations with chronic kidney disease, diabetes, and heart failure. Patiromer plus standard therapy was associated with fewer total adverse events than placebo plus standard therapy, although the proportion of patients experiencing at least one adverse event did not differ significantly. Adding patiromer to standard combination therapy did not produce statistically significant efficacy over placebo for urgent hyperkalaemia in the emergency department. Real-world emergency department observational studies have not consistently shown significant benefit for patiromer compared with insulin or sodium zirconium cyclosilicate. Patiromer is a non-absorbed cation-exchange polymer that binds potassium in the gastrointestinal tract. Because patiromer is not systemically absorbed, a ventricular tachycardia event in a patiromer patient was considered more likely attributable to hyperkalaemia itself.